Navigation Links
Global RNA Interference (RNAi) Industry
Date:8/7/2012

NEW YORK, Aug. 7, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Global RNA Interference (RNAi) Industry

http://www.reportlinker.com/p0552809/Global-RNA-Interference-RNAi-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Biologica

This report analyzes the worldwide markets for RNA Interference (RNAi) in US$ Million by the following Application Areas: Drug Discovery and Target Validation, Reagents, and siRNA Synthesis. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2009 through 2017. Also, a six-year historic analysis is provided for these markets. The report profiles 135 companies including many key and niche players such as Alnylam Pharmaceuticals, Inc., Benitec Limited, Bioneer Corp., Calando Pharmaceuticals, Inc., Cenix BioScience GmbH, Devgen NV, Dharmacon, Inc., Dicerna Pharmaceuticals, Inc., Exiqon A/S, Genesis Research & Development Corporation Limited, Halo-Bio RNAi Therapeutics, Inc., Marina Biotech, Inc., OPKO Health, Inc., Polyplus-transfection SA, Quark Pharmaceuticals, Inc., Galena Biopharma, Sigma-Aldrich Co., Silence Therapeutics, and Tekmira Pharmaceuticals Corp. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based upon search engine sources in the public domain.

To order this report:Biological Therapy Industry: Global RNA Interference (RNAi) Industry

More  

Market Research Report

Check our  

Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: nicolasbombourg@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626


'/>"/>
SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. MedImmune Announces Winners of Its 6th Annual Global Abstract Competition
2. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
3. Global Cleantech Cluster Association Names New York City Startup Rentricity to Global Top 10 List
4. StemCyte Adds World Class Talent to its North America and Global Operations
5. Sequenom Named to NASDAQ Global Select Market
6. Synthetic Biology: Emerging Global Markets
7. MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim
8. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
9. Hemodialysis Machine Industry 2012 Global & China Market Research Report - ReportsnReports
10. MarketsandMarkets: Global Seed Treatment Market worth $3430.3 Million by 2016
11. Accuray Surpasses 600 Installations Globally
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... China Biologic Products, Inc. (NASDAQ: CBPO) ("China Biologic" or the ... today announced its financial results for the fourth quarter and ... Financial Highlights Total sales in the ... or increased by 13.6% in USD terms to $77.6 million ... Gross profit increased by 13.3% to $46.8 million ...
(Date:2/23/2017)... and NEW YORK , ... Lumeon , a leading digital health company, ... a provider of telemedicine and remote patient monitoring, ... for telemedicine reimbursements.  DN Telehealth ... patients, in real-time, extending consultations beyond a physical ...
(Date:2/23/2017)... TORONTO , Feb. 23, 2017 /PRNewswire/ - The ... Institute for Cancer Research (OICR) are pleased to report ... Series A financing, with Johnson & Johnson Innovation – ... investors include venture groups HealthCap, TPG Biotechnology Partners, and ... ...
(Date:2/23/2017)... SEATTLE , Feb. 23, 2017  Seattle,s upscale Capitol ... like a strange place for a head lice treatment salon ... nestled between a Tuscan restaurant and a French bistro on ... it,s perfect. "We aren,t just any old lice clinic, we ... to feel comfortable, and release some of the stigma associated ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/7/2017)... , Feb. 7, 2017 Zimmer Biomet ... in musculoskeletal healthcare, will present at the LEERINK Partners ... York Palace Hotel on Wednesday, February 15, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
(Date:2/2/2017)... 2017   TapImmune, Inc. (NASDAQ: ... in the development of innovative peptide and gene-based ... and metastatic disease, announced today it has successfully ... a second clinical lot of TPIV 200, the ... The manufactured vaccine product will be used to ...
Breaking Biology News(10 mins):